I'm considering investing in CGS after researching the company and I like what I see but I'm just unsure about one thing.
Can any investors with a deeper knowledge of the business comment on whether the ability to detect Alzheimers using a blood test have a detrimental effect on CGS's operations?
Could this mean less assessments using CGS tests?
Detecting Alzheimers with Blood Test
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CGS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
89.5¢ |
Change
-0.005(0.56%) |
Mkt cap ! $154.5M | |||
| Open | High | Low | Value | Volume |
| 90.0¢ | 90.0¢ | 89.0¢ | $63.98K | 71.53K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7155 | 89.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.0¢ | 4760 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| CGS (ASX) Chart |